Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Neuromed Pharmaceuticals Ltd.

Sriram Tyagarajan

Prasun K Chakravarty

Jared N Cumming

Michael D Altman

Jongwon Lim

Rui Liang

Ryan D Otte

Andrew M Haidle

James Patrick Jewell

Tony Siu

Timothy J Henderson

Wonsuk Chang

Benjamin Wesley Trotter

Min Lu

Matthew A Larsen

Brandon D Cash

Michael H Fisher

William H Parsons

Jianming Bao

Peter T Meinke

Joseph Leslie Duffy

Feng Ye

Debra L Ondeyka

Zahid Hussain

Howard C H Kuo

Matthew J Wyvratt

Paul E Finke

Ashok Arasappan

Steven L Colletti

F Anthony Romero

Feroze Ujjainwalla

Jason M Cox

Harold B Wood

Zhuyan Guo

John S Debenham

Derun Li

Subharekha Raghavan

XiaoXia Qian

Dongfang Meng

Cameron James Smith

Richard Berger

Hassan Pajouhesh

Weiguo Liu

Petr Vachal

Yanbing Ding

Hong Li

Pengcheng Patrick Shao

Thomas L Shih

Edward C Sherer

Yi Zang

Zhong Lai

Remond Moningka

Jiafang He

Revathi Reddy Katipally

Bishan Zhou

Patrick Shao

Michael A Plotkin

Aaron Zwicker

Michelle B Ayer

Jeffrey M Fisher, Legal Representative

Xiaoxia Qian

Joseph L Duffy

Zahid Hussian

Anthony Romero

The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors

Compounds of general formula (Ia), compounds of general formula (Ia'), compounds of general formula (Ib), compounds of general formula (Ib&#x2032;), compounds of general formula (I), compounds of general formula (I&#x2032;), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, R, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Benzo[b]thiophene compounds as STING agonists

Benzo[b]thiophene compounds as sting agonists

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis. 

Spirocyclic CETP inhibitors

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Substituted aryl sulfone derivatives as calcium channel blockers

Biaryl substituted pyrazole compounds are sodium channel blockers useful for the treatment of pain and other conditions. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more therapeutically active compounds.

Biaryl substituted pyrazoles as sodium channel blockers

Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.

Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers

The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.

C1 to C4 side chain modified nodulisporic acid analogs

Growing community of inventors

Edison, NJ, United States of America

Sriram Tyagarajan